Amsterdam, the Netherlands – 20 January 2016 – Our portfolio company Kuros Biosciences Ltd. (SIX:KURN formerly CYTN) (“Kuros”), a developer of innovative products for tissue repair and regeneration, today announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016, all 508,432,244 shares of Kuros Biosciences Ltd. are listed and freely tradable und the ticker symbol KURN on the SIX Swiss Exchange and include all former 108’015’276 Cytos Biotechnolgy AG shares.
LSP has co-lead a CHF 20 million private financing round of Kuros Biosurgery Holding in August 2015 and supported the company in the reversed merger process with Cytos Biotechnology AG. For LSP’s latest fund generation LSP 5, which only became active in late 2014, Kuros is the first company that becomes listed on the stock market. Kuros is developing innovative products for tissue repair and regeneration and possesses a late stage clinical pipeline of products for medical sealants and bone healing (othobiologics). A version of the company’s press release can be found here.
About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. LSP will participate with two funds in this financing, the LSP Health Economics Fund and the LSP 5 Fund. For more information, please visit lspvc.com.
